ReviewViruses2013
Human cytomegalovirus manipulation of latently infected cells.
Review in Viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Associations between human cytomegalovirus infection and type 2 diabetes mellitus: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Global transcriptional reprogramming by cytomegalovirus infection suppresses MHC class II antigen presentation while enhancing migration machinery in murine dendritic cells.Microbial genomics · 2025Article
- Current Knowledge on the Interaction of Human Cytomegalovirus Infection, Encoded miRNAs, and Acute Aortic Syndrome.Viruses · 2023Review
- Review
- Cytomegalovirus infection: friend or foe in rheumatoid arthritis?Arthritis research & therapy · 2021Review
- Protein S-Nitrosylation of Human Cytomegalovirus pp71 Inhibits Its Ability To Limit STING Antiviral Responses.Journal of virology · 2020Article
- Where do we Stand after Decades of Studying Human Cytomegalovirus?Microorganisms · 2020Review
- Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?Frontiers in cellular and infection microbiology · 2020Review
- Expanding the Known Functional Repertoire of the Human Cytomegalovirus pp71 Protein.Frontiers in cellular and infection microbiology · 2020Review
- The Transcriptome of Latent Human Cytomegalovirus.Journal of virology · 2019Review
- Human cytomegalovirus G protein-coupled receptor US28 promotes latency by attenuating c-fos.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Human Cytomegalovirus UL135 Interacts with Host Adaptor Proteins To Regulate Epidermal Growth Factor Receptor and Reactivation from Latency.Journal of virology · 2018Article
- The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth.Oncogene · 2018Article
- Article
- A constant companion: immune recognition and response to cytomegalovirus with aging and implications for immune fitness.GeroScience · 2017Review
- Modulation of the Host Environment by Human Cytomegalovirus with Viral Interleukin 10 in Peripheral Blood.The Journal of infectious diseases · 2017Article
- Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein.Nature communications · 2017Article
- Latent human cytomegalovirus enhances HIV-1 infection in CD34Blood advances · 2017Article
- Article
- Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.Cancer cell international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Primary infection with human cytomegalovirus (HCMV) results in the establishment of a lifelong infection of the host which is aided by the ability of HCMV to undergo a latent infection. One site of HCMV latency in vivo is in haematopoietic progenitor cells, resident in the bone marrow, with genome carriage and reactivation being restricted to the cells of the myeloid lineage. Until recently, HCMV latency has been considered to be relatively quiescent with the virus being maintained essentially as a "silent partner" until conditions are met that trigger reactivation. However, advances in techniques to study global changes in gene expression have begun to show that HCMV latency is a highly active process which involves expression of specific latency-associated viral gene products which orchestrate major changes in the latently infected cell. These changes are argued to help maintain latent infection and to modulate the cellular environment to the benefit of latent virus. In this review, we will discuss these new findings and how they impact not only on our understanding of the biology of HCMV latency but also how they could provide tantalising glimpses into mechanisms that could become targets for the clearance of latent HCMV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.